Non-doxorubicin-containing chemotherapy combinations used in the treatment of desmoid tumors

Regimen	Number of patients	Duration of therapy	Response	Range of duration of response (in months)*	Author; year
MTX plus VLB^¶	30	38 weekly cycles over 390 days	0 CR 12 PR 18 MR/SD	5 to 127	Azzarelli A; 2001
MTX plus VLB^¶	26	2.5 to 12 (median 10) months	1 CR 4 PR, 3 MR 10 SD, 8 PD	2.1 to 71	Skapec S; 2007
MTX plus VLB	10	2 to 35 months	3 CR 2 PR 5 SD	2 to 51 (median 31)	Skapec S; 1998
MTX plus VLB	8	1 to 12 months	2 CR 5 PR 1 MR	2 to 30 (median 6)	Weiss A; 1989
MTX plus VLB	5	12 months	2 CR 1 PR 1 MR 1 SD	7 to 76^Δ	Reich S; 1999
MTX plus VLB	29	NR	21 PR or SD	NR	Dileo P; 2008
MTX plus VLB	18	3 weeks to 1 year	2 PR 11 SD 4 PD	1 to 192	Constantinidou A; 2010
MTX plus VLB	27	Median 18 weeks	4 PR 14 SD	1 to 145^§	Garbay D; 2012
VCR plus DACT plus Cy	6	3 weeks to 13 months	4 CR^◊ 1 PR 1 PD	28.4 to 140	Raney B; 1987
MTX plus NVB	17	NR	3 CR 7 PR 2 MR 3 SD	0.1 to 0.9 years	Weiss A; 1999

MTX: methotrexate; VLB: vinblastine; CR: complete response; PR: partial response; MR: minor response; SD: stable disease; PD: progressive disease; NR: not reported; VCR: vincristine; DACT: actinomycin D; Cy: cyclophosphamide; NVB: vinorelbine.
* Measured from onset of therapy.
¶ Prospective phase II trial.
Δ Duration of response was counted from the end of therapy. Treatment duration was listed as 12 months, but the authors did not provide individual data on treatment duration.
◊ 2 patients who attained a CR also received radiation therapy (5600 cGy) after 15 to 18 cycles.
§ Range of duration of progression-free survival for 49 patients treated with a non-anthracycline-containing chemotherapy regimen, 27 of whom received MTX plus VLB.

Graphic 81000 Version 10.0

خرید پکیج

Non-doxorubicin-containing chemotherapy combinations used in the treatment of desmoid tumors